Non-surgical Volume Enhancement with Fillers in the Orbit and Periorbital Tissues: Cosmetic and Functional Considerations

Ana M. Susana Morley,Raman Malhotra

DOI: https://doi.org/10.1007/978-3-540-85542-2_15

2010-01-01

Abstract:Abstract Orbital or periorbital volume loss may be due to factors other than aging. Any sinister, progressive, or reversible etiology should be identified and addressed prior to embarking upon volume replacement. Injectable soft-tissue fillers offer titratable volume augmentation, precise soft-tissue placement, the ability to be performed in the office, biocompati-bility, low down-time, minimal morbidity, high safety and, in most cases, potential reversibility. The two main types of injectable soft-tissue fillers are collagen and stabilized hyaluronic acid. The latter can be instantly dissolved using hyaluroni-dase. Nonanimal stabilized hyaluronic acid fillers are the most commonly used in orbital and periorbital volume augmentation. Fillers with larger particle size have increased viscos-ity reduced ease of injection and increased duration. On average, a medium viscosity hyaluronic acid gel will last a year when injected in a pre-periosteal plane in the periorbital region or in the orbit. Soft-tissue fillers have been successfully used for volume augmentation in the orbit (both sighted and anophthalmic), the tear trough, the upper eyelid/sub-brow region and in the brow and temple region. 2 ml of hyaluronic acid filler, administered to the orbit via an inferotemporal peribulbar injection and placed posterior to the equator of the globe or implant, usually reduces enophthalmos by up to 2 mm and restores the signs of periorbital volume deficiency. A serial-puncture technique, with deep pre-periosteal placement of small aliquots of filler, followed by molding and massage of the gel, is recommended for filling in periorbital region. Typical side effects of periorbital filler injection include bruising and mild swelling, although these usually resolve within a few days and can be concealed with make-up or glasses. Lumpiness can be a problem in a minority of patients but usually settles. Persistent lumpiness can be corrected with further molding, additional filler or, in the case of hyaluronic acid fillers, dissolution with hyaluronidase. Patient satisfaction following periorbital soft- tissue filler for rejuvenation is between 80–95%. The role of injectable soft-tissue fillers in treating periorbital pathology is continuing to expand, with reports of their successful use in treating paralytic lagophthalmos, lower eyelid retraction and cicatricial ectropion.